Phillip Minar, MD, MS
- Medical Director, Shubert-Martin Inflammatory Bowel Disease Center
- Program Director, Advanced Pediatric IBD Fellowship Training
- Associate Professor, UC Department of Pediatrics
- phillip.minar@cchmc.org
- Board Certified
About
BA: Duquesne University, Pittsburgh, PA.
MS: Clinical and Translational Research, University of Cincinnati, Cincinnati, OH.
MD: Medical College of Wisconsin, Milwaukee, WI.
Residency: Pediatrics, Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, WI.
Fellowship: Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Certification: General Pediatrics; Pediatric Gastroenterology.
Interests
Pediatric inflammatory bowel disease; evidence-based care for children and young adults with IBD; sustained, prednisone-free clinical remission
Services and Specialties
Inflammatory Bowel Disease, Inflammatory Bowel Disease IBD, Gastroenterology
Interests
Application of personalized medicine in the care of children and young adults with IBD through the discovery of surrogate biomarkers of intestinal inflammation; sensitive and specific pharmacodynamic biomarker, neutrophil CD64; innovative pharmacokinetic dosing platform, RoadMAB; personalized dosing of biologic therapies for patients with IBD; novel method to dose infliximab (guided by RoadMAB) from the start of treatment and throughout the maintenance phase to assess both the effectiveness and safety of model-informed precision dosing.
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
The Role of Therapeutic Drug Monitoring in Children. Gastroenterology Clinics of North America. 2023; 52:549-563.
Racial Disparities in Pediatric Inflammatory Bowel Disease Care: Differences in Outcomes and Health Service Utilization Between Black and White Children. The Journal of Pediatrics. 2023; 260:113522.
Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023; 29:1342-1346.
Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial. Gastroenterology. 2023; 165:149-161.e7.
Transcriptome analysis in acute gastrointestinal graft-versus host disease reveals a unique signature in children and shared biology with pediatric inflammatory bowel disease. Haematologica: the hematology journal. 2023; 108:1803-1816.
Su1884 ACUTE PANCREATITIS IS ASSOCIATED WITH GUT DYSBIOSIS IN CHILDREN. Gastroenterology. 2023; 164:s-703.
Su1013 EVALUATION OF INSURANCE TYPE ON PRIOR AUTHORIZATION (PA) DELAYS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS PRESCRIBED BIOLOGIC THERAPIES. Gastroenterology. 2023; 164:s-504-s-505.
860 ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN'S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP. Gastroenterology. 2023; 164:s-188.
513 DISPARITIES IN OSTOMY CREATION FOR PERIANAL FISTULIZING COMPLICATIONS IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE WITHIN A MULTI-INSTITUTIONAL COHORT. Gastroenterology. 2023; 164:s-1477.
347 DISEASE PROGRESSION PHARMACOKINETIC MODELING IMPROVES THE ACCURACY OF EARLY INFLIXIMAB CONCENTRATION TARGETS. Gastroenterology. 2023; 164:s-59.
From the Blog
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2023 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey